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Purpose: Surgical therapy is the primary treatment for oral cancer, but it can cause 
facial distortion. Therefore, if anticancer drugs are effective against oral cancer, 
they may be used preferentially. However, oral squamous carcinoma cells (OS-
CCs) are resistant to these drugs, so finding a way to enhance the sensitivity of 
these cells to anticancer drugs is important. The bacterial protein azurin is known 
to selectively enter cancer cells and induce apoptosis. In this study, we show the 
anticancer effect of azurin in OSCC. Materials and Methods: OSCC cell line 
(YD-9) was subjected to azurin treatment. Cell viability, morphology and protein 
expression levels were monitored after treatment of azurin. Cells were also sub-
jected to combination treatment of azurin with either 5-fluorouracil or etopside. 
Results: Azurin-treated cells showed decreased cell viability accompanied by 
apoptotic phenotypes including morphological change, DNA breakage, and in-
creases in p53 and cyclin B1 protein levels. Combination treatment of azurin with 
other anti-tumor agents caused an increase in sensitivity to anticancer drugs in 
azurin-treated YD-9 cells. Conclusion: Azurin has a strong synergistic anticancer 
effect on oral cancer cells when it is used along with anticancer drugs.
Key Words:    Azurin, oral squamous carcinoma, osteosarcoma, 5-fluorouracil, eto-
poside
INTRODUCTION
Oral cancer is one of the 10 most frequently occurring cancers worldwide,1 with 
more than 90% of malignancies being oral squamous cell carcinoma (OSCC), 
which originates from the oral mucosa. OSCC resistance to drugs may be circum-
vented by combining drugs, because the drugs can activate alternate apoptotic path-
ways when used in combination. Therefore, the clinical application of a combina-
tion of drugs may have synergistic effects, reducing resistance and/or cytotoxicity.2
Azurin, a cupredoxin type of electron transfer and purified low molecular weight 
redox protein from the pathogenic bacteria Pseudomonas aeruginosa, selectively 
induces and triggers apoptosis in certain human cancer cells. Recently, Yamada, et Jeong-Hae Choi, et al.
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anticancer drugs, YD-9 and MG-63 cells were cultured in a 
96-well plate. After 24 hours of incubation, the medium 
was replaced with fresh medium containing various con-
centrations of 5-fluorouracil (5-FU, Choongwae Pharma 
Corporation, Seoul, Korea) or etoposide (Sigma, St. Louis, 
MO, USA) along with 200 μg/mL azurin.
Cell growth assay
The cells were suspended in a 96-well plate (SPL Life Sci-
ence, Pocheon, Korea) at a density of 2×104 cells per well. 
After 24 h, they were treated with various concentrations of 
azurin, 5-FU, or etoposide for different periods of time (0-
72 h). Next, the cells were treated with 1 mg/mL MTT in the 
growth medium for 4 h at 37°C. Cell viability was evaluated 
by comparison with a control culture (assumed to be 100% 
viable), measuring the intensity of the blue color (OD at 570 
nm) using a multi-well reader (Quant, Bio-Tek, Highland 
Park, VT, USA).
Fluorescence microscopy
The cells were washed with cold PBS and incubated with 
4 μg/mL of Hoechst 33342, a DNA-binding fluorescent 
dye, for 30 min at 37°C in the dark. Then, the cells were 
fixed using 4% paraformaldehyde for 10 min. The morpho-
logical characteristics of the apoptotic cells were identified 
under a fluorescent microscope (ECLIPSE E800, Nikon, 
Tokyo, Japan) with excitation at 540 nm.
Hemacolor staining
The cells were prepared on microscope slides, air dried, 
and then immersed in a fixative solution. These slides were 
immersed in color reagent red and blue solution. The cells 
were washed twice with PBS and mounted in 50% glycerol 
in PBS. The morphological characteristics of the cells were 
examined under an optical microscope (Zeizz Axioskop, 
Oberkochen, Germany).
DNA fragmentation assay
The cells (2×106) were resuspended in 1.5 mL lysis buffer 
[10 mM Tris (pH 7.5), 10 mM EDTA (pH 8.0), 10 mM NaCl, 
and 0.5% SDS] containing proteinase K (200 µg/mL). After 
overnight incubation at 48°C, 200 μL of ice-cold 5 M NaCl 
was added to the suspended cells and fragmented DNA was 
collected by ethanol precipitation. Approximately 7 μg of 
DNA from each sample was electrophoresed through a 2% 
agarose gel containing 0.5 μg/mL ethidium bromide. The 
DNA was visualized under UV light and photographed.
al.3 reported that azurin can effectively enter human cancer 
cells but not normal cells. After internalization, azurin 
forms a complex with the tumor suppressor protein p53 and 
stabilizes it,4 thereby inducing apoptosis or cell cycle arrest 
in the G1 phase.5,6
Despite extensive analysis of azurin’s antitumor activity, 
its ability to modulate oral cancer growth has not yet been 
characterized. In this study, the antitumor effect of azurin on 
YD-9 and MG-63 cells is elucidated. Azurin controls p53 
and cyclin B1 protein levels, leading to apoptosis of OSCC. 
Furthermore, combination treatment of azurin with 5-fluo-
rouracil or etoposide effectively increases the sensitivity of 
OSCC to anticancer drugs. 
MATERIALS AND METHODS
　　　
Cloning and purification of azurin
The azurin gene was amplified using PCR with genomic 
DNA of the P. aeruginosa strain as the template DNA. 
Primer sequences were 5’-GCCCAAGCTTACCTAG-
GAGGCTGCTCCATGCTA-3’ and 5’-TGAGCCCCTG-
CAGGCGCCCATGAAAAAGCCCGGC-3’; the addition-
ally introduced HindIII and PstI sites are underlined. A 
plasmid expressing GST-tagged azurin was constructed by 
introducing it into pGEX-4T-2. To purify the azurin protein, 
BL21 (DE3) cells were used as the host strain. After induc-
tion with 1 mM IPTG, GST-fusion proteins were purified 
from cell extracts, with affinity chromatography using an 
ÄKTA FPLC system (Amersham Biosciences, Little Chalf-
ont, UK). Next, 5 µg of purified protein was used for 15% 
SDS-PAGE and stained with staining buffer containing 
Coomassie brilliant blue.
Cell culture
The YD-9 cell line established from an OSCC patient (ob-
tained from the Korean Cell Line Bank) and the human osteo-
sarcoma cell line MG-63 (ATCC, CRL-1427, HTB 96, Manas-
sas, VA, USA) were used in this study. The cells were cultured 
in Dulbecco’s modified Eagle medium (Gibco, NY, USA) 
with nutrient mixture F12 (DMEM/F12, 3:1) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, GIB-
CO), 1% glutamine and 100 µg/mL penicillin/streptomycin 
at 37°C in a humidified incubator with 5% CO2 atmosphere.
Combination treatment of azurin and anticancer drugs
To elucidate the effects of purified azurin combined with Anti-Tumor Effect of Azurin on Oral Cancer Cells
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of the purification procedure: 14 kDa azurin, which was 
pure enough to be used for cell treatment assays.
 
Treatment of azurin inhibits the growth of YD-9 cells
To elucidate the effects of purified azurin on OSCC, YD-9 
cells were subjected to azurin treatment and their growth 
was monitored (Fig. 2A). Azurin decreased the viability of 
YD-9 cells in a dose-dependent manner, and 200 μg/mL 
azurin reduced cell growth by up to 50%. In the next step, the 
cell cytotoxic activity of purified azurin was tested at various 
time points. Interestingly, treatment of MG-63 osteosarco-
ma cells with 200 μg/mL azurin had no effect on growth, 
whereas treatment of YD-9 cells with 200 μg/mL azurin ef-
ficiently inhibited growth in a time-dependent manner. The 
decreased growth rates of YD-9 cells were about 25%, 50%, 
and 60% at 24, 48, and 72 h, respectively.
Azurin induces apoptosis of YD-9 cells
As Fig. 3A. shows, treatment with azurin effectively de-
creased the total number of cells and was accompanied by 
shrinkage and shape changes. When the cells were stained 
using the hemacolor staining method, which can discrimi-
nate between apoptosis and necrosis (Fig. 3B), condensed 
nuclei and an increase in apoptotic bodies were observed in 
azurin-treated cells. This phenotype was also observed when 
the nuclei of cells were stained with Hoechst 33342 (Fig. 3C). 
Western blot analysis
The cells were harvested with a cold cell lysis buffer (RIPA 
solution; 10 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% 
deoxycholate, 0.1% SDS, 5 mM EDTA, pH 7.4) and the pro-
tein concentration was determined using the Brad-Ford pro-
tein assay. Cell lysates (50 µg) were used for SDS-PAGE 
coupled with western blot analysis. Antibodies against p53, 
Cdc2, cyclin B1 and beta-actin were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA) and anti-mouse 
or anti-rabbit HRP- conjugated secondary IgG (Amersham 
Biosciences, Little Chalfont, UK) were used as a secondary 
antibody. Detection was carried out by incubating the mem-
brane with an enhanced chemililuminescence reagent kit 
(Amersham Biosciences, Little Chalfont, UK).
RESULTS
 
Cloning of the pGEX-4T-2-azuA construct and 
purification of azurin
Plasmids expressing GST-tagged azurin were cloned as in-
dicated in the Materials and Methods section. As Fig. 1A. 
shows, this construct harbored the GST-tagged full-length 
azurin gene amplified from P. aeruginosa. This construct 
was transformed into an E. coli strain, BL21 (DE3), in order 
to obtain purified azurin. Fig. 1B. shows the final product 
Fig. 1. Extraction and purification of azurin from bacteria: (A) A schematic diagram of GST-tagged full length azurin (B) Expression of puri-
fied azurin protein: GST-azurin protein was amplified in bacteria and purified, as indicated in Materials and Methods. M: protein marker.
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treatment, but the level of cyclin B1 dramatically increased. 
Azurin enhances sensitivity of YD-9 and MG-63 cells to 
anticancer drugs
Since no anticancer drug developed to date can destroy all 
cancer cells, the effects of treatment with azurin in combi-
nation with other anticancer drugs were tested. 5-FU is one 
of the most frequently used drugs for treating oral cancer. 
Because of the variation in sensitivity of tumor cells to 5-FU, 
the effect of 5-FU on YD-9 and MG-63 cells was tested 
(Fig. 4A). Treatment of YD-9 cells and MG-63 cells with 
These results imply that azurin can induce apoptosis of YD-9 
cells; therefore, DNA fragmentation was examined after 
azurin treatment. Fig. 3D shows that azurin treatment for 
24 h was enough to induce DNA fragmentation. 
In order to understand the molecular mechanisms induc-
ing apoptosis after azurin treatment, the level of proteins in-
volved in cell cycle regulation and apoptosis were monitored 
(Fig. 3E). The cellular p53 level increased within 8 hours of 
treatment and then decreased slightly in a time-dependent 
manner. Levels of Cdc2, which forms a complex with cyclin 
B1 during the G2/M transition, did not change with azurin 
Fig. 2. Azurin inhibits the viability of YD-9 cells. (A) YD-9 cells were treated with various concentrations of azurin as indicated. After 48 h of in-
cubation, cell growth was tested. Data shown are the average of 4 independent experiments, with a mean value of p<0.03. (B) YD-9 and MG-
63 cells were treated with 200 μg/mL azurin and incubated for 24, 48, and 72 h as indicated, and cell viability was tested. Mean value, p<0.04.
Fig. 3. Azurin triggers apoptosis of YD-9 cells. Morphological changes in YD-9 cells after 24 h incubation in the presence or absence of 
200 μg/mL azurin, as observed with simple microscopy (A) and after cell staining with hemacolor (B) or Hoechst 33352 (C). (D) DNA frag-
mentation of 200 μg/mL azurin-treated cells occurred in a time-dependent manner. (E) YD-9 cells were exposed to 200 μg/mL azurin for in-
dicated times. Total protein (30 μg) was subjected to SDS-PAGE and western blotting. Data shown is the representative of 3 independent 
experiments. M, DNA marker; C, Control (lysate of untreated cells).
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pression has been reported to be induced and this protein is 
reported to be active during stress-induced apoptosis in va-
rieties of cancer cells, indicating that cyclin B1 participates 
in apoptosis.8-10 In keeping with these earlier findings, our 
data show that azurin effectively induces DNA fragmenta-
tion of YD-9 cells (Fig. 3D) along with increased expres-
sion of cyclin B1, indicating that increased cyclin B1 may 
play a role in azurin-induced apoptosis. The same set of ex-
periments as in Fig. 3 was also performed using MG-63 cells 
after azurin treatment, but there were no significant differ-
ences (Data not shown).
In the final step of this study, we investigated azurin’s abili-
ty to sensitize YD-9 and MG-63 cells to anticancer drugs. 
5-FU was initially used in chemotherapy for gastrointesti-
nal, breast, pancreas, and skin neoplasms. Although 5-FU 
remains a widely used chemotherapeutic agent for head and 
neck squamous cell carcinoma (HNSCC), its clinical im-
portance has been decreasing in recent times because a num-
ber of HNSCCs are resistant to this agent.11 As shown in Fig. 
4A, YD-9 and MG-63 cells have a strong resistance to 5-FU. 
When 5-FU was administered in combination with azurin, 
the viability of both cell lines was greatly decreased. Given 
that azurin alone does not have a cytotoxic effect on p53-null 
MG-63 cells, this result indicates azurin can enhance the sen-
sitivity of MG-63 cells to 5-FU in a p53-independent man-
5-FU alone resulted in approximately 30% growth inhibition 
at 1 mM. In contrast, when 5-FU was administered in combi-
nation with azurin, 10 μM 5-FU was enough to cause 80-
90% growth inhibition. The synergistic effect of azurin on et-
oposide-induced apoptosis was also confirmed (Fig. 4B). 
DISCUSSION
   
Here, we demonstrate the effects of azurin as an anti-oral 
cancer drug. The MTT assay showed that azurin effectively 
inhibits YD-9 oral cancer cell growth (Fig. 2A). Azurin treat-
ment also increased the number of cells with apoptotic phe-
notypes (Fig. 3A-D). On the other hand, azurin treatment did 
not cause cytotoxicity of MG-63 osteosarcoma cells (Fig. 
2B). This result was further confirmed by BrdU assay (data 
not shown). Another group reported that azurin had no effect 
on MG-63 cells, and they argued that this was caused by 
the lack of p53 in MG-63 cells.7 Fig. 3E shows that treating 
YD-9 cells with azurin enhances p53 expression, indicating 
that this increase in p53 might cause cell death. Interesting-
ly, along with p53, expression of the cell-cycle regulator 
cyclin B1 was also enhanced by azurin treatment. The pos-
sible role of cyclin B1 in several DNA-damaging processes 
that induce apoptosis has been suggested. Cyclin B1 ex-
Fig. 4. Azurin enhances sensitivity of YD-9 and MG-63 cells to 5-fluorouracil and etoposide. YD-9 and MG-63 cells were treated with 10-
1,000 μM of 5-fluorouracil (5-FU) (A) or 2-10 μg/mL etoposide (B) along or not along with 200 μg/mL azurin as indicated for 24 h and sub-
jected to a cell growth assay. Data shown are representative of 4 independent experiments, with p<0.02.
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malian cells: entry domain and specificity. Cell Microbiol 2005;7: 
1418-31. 
4. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, et 
al. Bacterial redox protein azurin, tumor suppressor protein p53, 
and regression of cancer. Proc Natl Acad Sci U S A 2002;99: 
14098-103. 
5. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, 
Graves J, et al. Bacterial cupredoxin azurin as an inducer of apop-
tosis and regression in human breast cancer. Oncogene 2004;23: 
2367-78. 
6. Yamada T, Goto M, Punj V, Zaborina O, Kimbara K, Das Gupta 
TK, et al. The bacterial redox protein azurin induces apoptosis in 
J774 macrophages through complex formation and stabilization of 
the tumor suppressor protein p53. Infect Immun 2002;70:7054-62. 
7. Yang DS, Miao XD, Ye ZM, Feng J, Xu RZ, Huang X, et al. Bac-
terial redox protein azurin induce apoptosis in human osteosarco-
ma U2OS cells. Pharmacol Res 2005;52:413-21. 
8. Borgne A, Versteege I, Mahé M, Studeny A, Léonce S, Naime I, 
et al. Analysis of cyclin B1 and CDK activity during apoptosis in-
duced by camptothecin treatment. Oncogene 2006;25:7361-72. 
9. Porter LA, Singh G, Lee JM. Abundance of cyclin B1 regulates 
gamma-radiation-induced apoptosis. Blood 2000;95:2645-50. 
10. Porter LA, Cukier IH, Lee JM. Nuclear localization of cyclin B1 
regulates DNA damage-induced apoptosis. Blood 2003;101:1928-
33. 
11. Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M, Shintani S. Hy-
poxia induces resistance to 5-fluorouracil in oral cancer cells via 
G(1) phase cell cycle arrest. Oral Oncol 2009;45:109-15. 
12. Gomez LA, de Las Pozas A, Reiner T, Burnstein K, Perez-Stable 
C. Increased expression of cyclin B1 sensitizes prostate cancer 
cells to apoptosis induced by chemotherapy. Mol Cancer Ther 
2007;6:1534-43. 
ner. This sensitizing ability of azurin was further confirmed 
by combination treatment with etoposide (Fig. 4B). Accord-
ing to a report by Gomez, et al.,12 increased expression of 
cyclin B1 sensitizes cancer cells to chemotherapy-induced 
apoptosis. Therefore, the increase in cyclin B1 levels induced 
by azurin could be part of the molecular mechanism under-
lying azurin-induced sensitization of YD-9 and MG-63 
cells to 5-FU and etoposide. Given the results of this study, 
future investigation is required.
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